Chengbin Wu

USPTO Granted Patents = 22 (Patent Applications = 32)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 3.1

ph-index = 11

Forward Citations = 827(Granted Patents)

Location History:

Shrewsbury, MA (US) (2009 - 2015)
Shanghai, CN (2013 - 2024)

Company Filing History:

Abbott Laboratories Corporation

patents

3 out of 3

Epimab Biotherapeutics, Inc.

patents

4. 1 out of 1

Shanghai Epimab Biotherapeutics Co., Ltd.

patent

Years Active: 2009-2024

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060425 - High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom (2024-08-13),

2. 11421028 - Fabs-in-tandem immunoglobulin and uses thereof (2022-08-23),

3. 11344621 - Interleukin-13 binding proteins (2022-05-31),

4. 10519251 - Fabs-in-tandem immunoglobulin and uses thereof (2019-12-31),

5. 10266608 - Fabs-in-tandem immunoglobulin and uses thereof (2019-04-23),

6. 10086076 - Interleukin-13 binding proteins (2018-10-02),

7. 9592293 - Interleukin-13 binding proteins (2017-03-14),

8. 9447184 - IL-1 binding proteins (2016-09-20),

9. 9447183 - IL-1 binding proteins (2016-09-20),

10. 9441038 - IL-1 binding proteins (2016-09-13),

11. 9409986 - IL-1 binding proteins (2016-08-09),

12. 9303085 - IL-1 binding proteins (2016-04-05),

13. 9035027 - Dual variable domain immunoglobulins and uses thereof (2015-05-19),

14. 8853365 - Dual variable domain immunnoglobulins and uses thereof (2014-10-07),

15. 8841417 - IL-1 binding proteins (2014-09-23),

Title: Chengbin Wu: Innovator in Bispecific Antibodies and Multivalent Binding Proteins

Introduction

Chengbin Wu, based in Shanghai, CN, is an accomplished inventor known for his significant contributions to the field of biotherapeutics. With a remarkable portfolio of 22 patents, he has focused his research on innovative solutions aimed at treating cancer and improving healthcare outcomes.

Latest Patents

Among his latest patents, Chengbin has developed high-affinity antibodies targeting Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 (LAG-3). His invention describes bispecific binding proteins that can bind to both PD-1 and LAG-3 simultaneously, enhancing their therapeutic potential against cancer. Additionally, he has created multivalent and multispecific binding proteins designed to bind two or more antigens or epitopes. These advancements pave the way for novel methods of preventing or treating various diseases and detecting specific antigens, which could transform clinical practices.

Career Highlights

Chengbin has made significant strides in his career, notably working with prestigious companies such as AbbVie Inc. and Abbott Laboratories Corporation. His expertise in biopharmaceuticals has not only led to groundbreaking inventions but also established him as a prominent figure in the field.

Collaborations

Throughout his successful career, Chengbin has collaborated with talented researchers, including Tariq Ghayur and Dominic J Ambrosi. These partnerships highlight the collaborative nature of scientific research and innovation, further enhancing the quality and impact of his work.

Conclusion

In conclusion, Chengbin Wu's innovative contributions to the development of bispecific antibodies and multivalent binding proteins mark him as a leading inventor in the pharmaceutical industry. His 22 patents reflect a commitment to advancing medical science and improving therapeutic approaches for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.